EHS
EHS

OTX-TKI shows promising results in wet AMD


October 01, 2022

2 min watch

Source:

Kaiser P. Ocular Therapeutix. Presented at: Eyecelerator@AAO; Sept. 29, 2022; Chicago.

Disclosures:
Kaiser reports consulting for Bayer, Ocular Therapeutix and Regeneron.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — In this video from Eyecelerator@AAO, Peter Kaiser, MD, discusses data from a phase 1 clinical study investigating OTX-TKI for the treatment of wet age-related macular degeneration.

In the randomized double-masked study, patients were randomly assigned to receive either OTX-TKI (axitinib intravitreal implant) or aflibercept every 8 weeks. According to Kaiser, chief medical advisor, retina, Ocular Therapeutix, OTX-TKI had positive results, showing a “dramatic reduction in treatment burden” in the treated cohort.



Source link

EHS
Back to top button